Chronic Inflammatory Demyelinating Polyneuropathy Market - Global Forecast 2025-2032

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is evolving rapidly, presenting industry leaders with emerging opportunities and ongoing challenges stemming from advances in care approaches, changes in therapy delivery, and a shifting policy environment. Executives must act strategically to position their organizations for sustainable growth and resilience.

Market Snapshot: Chronic Inflammatory Demyelinating Polyneuropathy Market Overview

The Chronic Inflammatory Demyelinating Polyneuropathy market has progressed from USD 2.49 billion in 2024 to USD 2.64 billion in 2025, with projections targeting USD 3.96 billion by 2032, yielding a consistent CAGR of 5.98%. This expansion is fueled by technological developments, evolving regulatory frameworks, and a strong emphasis on patient-centered outcomes. Market dynamics now favor organizations with innovative capabilities and readiness to adapt, as increased investment, clinical innovation, and operational solutions reshape the competitive landscape.

Scope & Segmentation

This report provides a comprehensive analysis of the CIDP market, enabling decision-makers to assess opportunities and risks across several strategic dimensions:

• Treatment Modalities: Analysis includes corticosteroid regimens, immunosuppressants such as azathioprine, cyclophosphamide, mycophenolate mofetil, and rituximab, alongside intravenous and subcutaneous immunoglobulin therapies, and plasma exchange. Each therapy’s operational and clinical impact is evaluated on decision-making pathways.
• End Users: Segmentation covers hospitals, home care, and specialty clinics, spotlighting how each setting influences patient care strategies, workflow, and resource allocation.
• Distribution Channels: The role of hospital pharmacies, online pharmacy platforms, and retail outlets in ensuring therapy access and patient support is thoroughly assessed.
• Patient Age Groups: Market analysis encompasses adult, pediatric, and geriatric populations, focusing on how management protocols are tailored according to age-related needs and vulnerabilities.
• Disease Severity: The spectrum of CIDP severity, from mild to severe, is examined in relation to therapy planning agility and patient outcome optimization.
• Regional Coverage: Coverage spans the Americas (notably the United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, and Peru), Europe, Middle East & Africa (including the United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, UAE, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, and Kenya), as well as Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan), with analysis reflecting local market drivers and healthcare infrastructure evolution.
• Key Companies: Competitive profiling includes Grifols, S.A.; CSL Behring AG; Octapharma AG; Takeda Pharmaceutical Company Limited; Baxter International Inc.; LFB S.A.; Kedrion S.p.A.; Biotest AG; Kamada Ltd.; and Shanghai RAAS Blood Products Co., Ltd.; examining product line strategies and geographic expansion.

Key Takeaways: Strategic Insights for Senior Decision-Makers

• Adoption of advanced neuroimaging and next-generation sequencing tools is improving diagnostic precision, allowing tailored therapies and more accurate patient classification.
• Regulatory evolution, with a focus on adaptive pathways and integration of real-world evidence, is streamlining therapy approval timelines and encouraging agility in neurology portfolios.
• Patient-centric care models, including telehealth and at-home infusion, are enhancing engagement, adherence, and extending value-based care beyond standard clinical environments.
• New tariffs on imported immunoglobulin products have prompted market participants to pursue localized production and diversified supply chains to counteract cost instability and ensure continuity.
• Partnerships, licensing, and collaborative initiatives are accelerating therapy development and reinforcing agility within the sector, strengthening both competitive positioning and operational excellence.

Tariff Impact on the Polyneuropathy Therapeutics Sector

The introduction of the 2025 United States tariff on critical therapeutic imports is driving CIDP manufacturers to re-examine supply chains. Companies are bolstering domestic production and engaging in risk-diversified sourcing through risk-sharing and volume-based contracts. Distribution and clinical supply players are adapting strategies to manage fluctuating supply patterns, while discussions between industry leaders and policymakers aim to seek exemptions for rare disease therapies. This evolving environment underscores the critical importance of inventory flexibility and agile procurement to protect patient access to essential treatments.

Methodology & Data Sources

Research for this Chronic Inflammatory Demyelinating Polyneuropathy market analysis integrates in-depth primary interviews with leading neurology, immunology, and policy authorities. A thorough review of secondary sources, such as published clinical studies and regulatory documents, complements expert insight. Supply chain and sector specialist feedback supports the reliability and validity of the report’s segmentation.

Why This Report Matters for Decision-Makers

• Offers actionable intelligence to help organizations direct investment toward promising treatments, focus on high-potential regions, and address each patient segment effectively for sustainable growth.
• Equips businesses to anticipate and adjust to international tariff changes and shifting supply chain models, supporting continuous patient care delivery.
• Provides a framework for benchmarking against industry trends and regulatory changes, advancing informed commercialization and partnership strategies.

Conclusion

The CIDP market landscape is being reshaped by ongoing innovation, evolving policies, and shifts in care delivery. Forward-thinking leaders can use insights from this report to develop adaptable strategies and strengthen positions across products, regions, and care models.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.